WITHDRAWN: Evaluating radiomics based predictors of survival under anti-PD1 therapy

Music City Center 

Radiomics, the extraction of quantitative features from medical images such as CT scans, may provide clinically relevant insights for cancer patient outcomes beyond the information provided by tumor size changes. Prior studies [Abbas et al 2023, Nardone et al 2024] have examined the changes in radiomic features at different time points (termed delta radiomics) to explore its potential as a longitudinal biomarker of cancer response. Additionally, existing studies have shown that delta radiomics (not baseline) has predictive power, with delta tumor volume being the most important feature. However, few radiomics-based biomarkers have been externally validated. Here, we developed a CT-based radiomic signature score for TNBC and bladder cancer to predict association with survival outcome under pembrolizumab monotherapy. Using a penalized Cox regression model and size-change detrended radiomics features analysis, our findings suggest that CT-based delta radiomics is predictive of survival outcomes but does not add value beyond delta volume.

radiomics

delta radiomics

biomarkers

oncology

survival 

Biopharmaceutical Section